89 related articles for article (PubMed ID: 1503482)
1. [Phase III study of DWA2114R for ovarian cancer].
Kato T; Yakushiji M; Nishimura H; Terashima Y; Sasaki H; Yamabe T; Yajima A; Fujimoto S; Hashimoto M; Nishiya I
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1285-93. PubMed ID: 1503482
[TBL] [Abstract][Full Text] [Related]
2. [Phase III study of carboplatin in ovarian cancer].
Kato T; Nishimura H; Yamabe T; Terashima Y; Kasamatsu T; Hirabayashi K; Nishiya I; Yajima A; Takamizawa H; Tsutsui F
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2297-304. PubMed ID: 3044276
[TBL] [Abstract][Full Text] [Related]
3. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
4. [Current status of CDDP analogs in gynecologic malignancies].
Yakushiji M; Nishimura H
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1393-8. PubMed ID: 2658828
[TBL] [Abstract][Full Text] [Related]
5. [A phase II study of DWA2114R, a new platinum complex for breast cancer].
Aoyama H; Kubo K; Uchino J; Hayasaka H; Asaishi K; Izuo M; Ogawa M; Majima H; Yasutomi M; Wada T
Gan To Kagaku Ryoho; 1992 Jul; 19(7):1033-9. PubMed ID: 1626939
[TBL] [Abstract][Full Text] [Related]
6. [Clinical results of carboplatin in the treatment of malignant tumors. Clinical Cooperative Group of Carboplatin].
Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):321-4. PubMed ID: 2177394
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
8. [Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
Kumagai M; Fujii T; Komatsu M; Kusuda T; Takehara K; Shinkou S; Naitou H
Gan To Kagaku Ryoho; 2004 Apr; 31(4):555-9. PubMed ID: 15114699
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.
Neijt JP; Engelholm SA; Witteveen PO; Tuxen MK; Sørensen PG; Hansen M; Hirsch F; Sessa C; de Swart C; van Houwelingen HC; Lund B; Hansen SW
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-36-S15-39. PubMed ID: 9346220
[TBL] [Abstract][Full Text] [Related]
13. [Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
Akamatsu K; Endo K; Tsunenari T; Matsumoto T; Kaiho S; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Gan To Kagaku Ryoho; 1992 Feb; 19(2):229-35. PubMed ID: 1736835
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
15. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
19. [Cisplatinum compounds].
Ota K
Gan To Kagaku Ryoho; 1993 Jan; 20(1):50-8. PubMed ID: 8380687
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]